Management of sunitinib-related adverse events: an evidence- and expert-based consensus approach
- 346 Downloads
The advance of medical treatment in renal cell carcinoma (RCC) has fostered the development of diverse continuous oral therapies with tyrosine kinase inhibitors (TKI), among these sunitinib remains the mainstay of therapy for most of the patients. Based on its clinical activity, disease control over a period of 11 months can be expected with sunitinib treatment. Given this prolonged period of exposure to sunitinib, adverse events tend to reoccur and can possibly decrease the quality of life in our patients. Hence, development of modalities to detect, treat and cope with such adverse events has become a major focus for physicians and patients. Today, numerous publications address these questions and offer advice from experienced centers. However, these reviews summarize single or oligo-center experiences.
Methods and Results
Our approach is based (1) on an extensive review and analysis of available evidence from literature and (2) a structured consensus survey among 12 German experts in the field who treated at least 30 patients each with a TKI.
Derived from this process, this paper gives an overview on Sunitinib therapy management recommendations deducted from published evidence and consensus agreement among experts.
KeywordsSunitinib Adverse events Management Survey
- 1.Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584–3590CrossRefPubMedGoogle Scholar
- 3.Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O’Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281CrossRefPubMedGoogle Scholar
- 11.Desai JG, Pavlakis H, McAarthur N, Davis ID GA (2007) Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: Recommendations for patient management. Asia-Pacific Journal of Clinical Oncology 3:167–176Google Scholar
- 13.Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen J-H, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:2011–2019CrossRefPubMedGoogle Scholar
- 15.Summary of product characteristics; sutent®Google Scholar
- 16.Di Lorenzo G, Autorino R, Bruni G, Cartenì G, Ricevuto E, Tudini M, Ficorella C, Romano C, Aieta M, Giordano A, Giuliano M, Gonnella A, De Nunzio C, Rizzo M, Montesarchio V, Ewer M, De Placido M (2009) Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 20:1535–1542CrossRefPubMedGoogle Scholar
- 19.Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer G, Patenaude F, Oudard S, Karakiewicz PI (2008) Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 53:917–930CrossRefPubMedGoogle Scholar
- 20.National comprehensive cancer network21® (nccn). Clinical practice guidelines in oncology™. Cancer-related fatigue (v.2.2007). Available at: http://www.Nccn.Org/professionals/physician_gls/pdf/fatigue.Pdf, 2007
- 21.Wood L (2006) Managing the side effects of sorafenib and sunitinib. Community Oncol 3:558–562Google Scholar
- 23.Staehler M, Haseke N, Schoppler G, Stadler T, Heinemann G, Stief CG (2006) managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma. Urologe A 2006;45:1333–1342; quiz 1343Google Scholar
- 24.Houk BE, Bello C, Michaelson MD, Bukowski RM, Redman BG, Hudes GR, et al. (2007) Exposure-response of sunitinib in metastatic renal cell carcinoma (mrcc): A population pharmacokinetic/pharmacodynamic (pkpd) approach. J clin Oncol ASCO Meeting Abstracts 25 Abstract: 5027Google Scholar
- 28.Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT, Anderson RT, Wood L, Dutcher JP (2008) Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13:1001–1011CrossRefPubMedGoogle Scholar